

1/29/96

Attachment to  
Paper #5

FORM PTO-1449 (Modified)  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Attorney Docket No. 11823-002630US	Serial No.: 08/484,537			
		Applicant: CARY L. QUEEN et al.				
		Filing Date: 06/07/95	Group: 1806			
Reference Designation		U. S. PATENT DOCUMENTS				
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
AA	4,578,335	03/25/86	Urdal et al.	530	351	
AB	4,816,565	03/28/89	Honjo et al.	435	69.1	
AC	4,816,397	03/28/89	Boss et al.	—	—	
AD	4,816,567	03/28/89	Cabilly et al.	—	—	
AE	4,845,198	07/04/89	Urdal et al.	530	387	05/21/84
AF	4,867,973	09/19/89	Goers et al.	—	—	09/13/84
AG	5,198,359	03/30/93	Taniguchi et al.	612N15	63	
AH	5,225,539	07/06/90-1/93	Winter	—	—	
FOREIGN PATENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (yes/no)
AI	0,171,496	02/19/86	EPO	—	—	
AJ	0,173,494	03/05/86	EPO	—	—	
AK	0,184,187	06/11/86	EPO	—	—	
AL	WO 86/05513	09/25/86	PCT	—	—	
AM	WO 87/02671	05/07/87	PCT	—	—	
AN	0,256,654	07/07/87	EPO	—	—	
AO	0,239,400	09/30/87	EPO	—	—	
AP	2,188,941	10/14/87	GB	—	—	
AQ	0,266,663	06/11/88	EPO	—	—	
AR	WO 89/01783	03/09/89	PCT	—	—	
AS						
EXAMINER	Julie Reevs PL			DATE CONSIDERED	29 Oct 97	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket No.  
11823-002630USSerial No.:  
08/484,537

Applicant: CARY L. QUEEN et al.

Filing Date: 06/07/95 Group: 1806

MAIL ROOM  
16 JAN 29  
1996  
PATENT & TRADEMARK OFFICE

## OTHER ART (Use several sheets if necessary) Author, Title, Date, Pertinent Pages, Etc.)

AT	Better et al. "Escherichia coli Secretion of an Active Chimeric Antibody Fragment," <u>Science</u> , 240:1041-1043 (1988)
AU	Bird et al., "Single-Chain Antigen-Binding Proteins," <u>Science</u> , 242:423-426 (1988)
AV	Boulianne et al., "Production of functional chimeric mouse/human antibody," <u>Nature</u> , 312:643-646 (1984)
AW	Carter et al., "Humanization of an anti-p185 <sup>HER2</sup> antibody for human cancer therapy," <u>Proc. Natl. Acad. Sci.</u> , 89:4285-4289 (1992)
AX	Chothia, C. and A.M. Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins," <u>J. Mol. Biol.</u> , 196:901-917 (1987)
AY	Co et al., "Humanized antibodies for antiviral therapy," <u>Proc. Natl. Acad. Sci.</u> , 88:2869-2873 (1991)
AZ	Co et al., "Chimeric and humanized antibodies with specificity for the CD33 antigen," <u>J. Immunol.</u> , 148:1149-1154 (1992)
BA	Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expansion of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <u>Nuc. Acids. Res.</u> , 19:2471-2476 (1991)
BB	Ellison et al., "The nucleotide sequence of a human immunoglobulin c(gamma) gene," <u>Nucleic Acids Res.</u> , 10:4071- (1982)
BC	Farrar, J., "The biochemistry, biology, and the role of interleukin-2 in the induction of cytotoxic T cell and antibody-forming B cell receptors," <u>Immunol. Rev.</u> , 63:129-166 (1982)
BD	Foote et al., "Antibody framework residues affecting the conformation of hypervariable loops," <u>J. Mol. Biol.</u> , 224:487-499 (1992)
BE	Gorman et al., "Reshaping a therapeutic CD4 antibody," <u>Proc. Natl. Acad. Sci.</u> , 88:4181-4185 (1991)
BF	Greene et al., "Growth of Human T Lymphocytes: An Analysis of Interleukin 2 and its Cellular receptor," <u>Progress in Hematology XIV</u> , E. Brown, ed., Grune and Statton, New York, pp. 283-301 (1986)
BG	Hale et al., "Remission Induction in Non-Hodgkin Lymphoma with Reshaped Human Monoclonal Antibody CAMPATH-1H," <u>Lancet</u> , December 17, 1988, pp. 1394-1399
BH	Hieter et al., "Cloned Human and Mouse Kappa Immunoglobulin Constant and J. Region Genes Conserve Homology in Functional Segments," <u>Cell</u> , 22:197-207 (1980)
BI	Huston et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli," <u>Proc. Nat. Acad. Sci. USA</u> , 85:5879-5883 (1988), <u>Progress in Hematology XIV</u> , E. Brown, ed., Grune and Statton, New York, p. 283, (1986)
BJ	Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <u>Nature</u> , 321:522-525 (1986)

EXAMINER Julie C Rees, P.H. DATE CONSIDERED 27 Oct 97

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)

Applicant: CARY L. QUEEN et al.

Filing Date: 06/07/95

Group: 1806

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Q BK	Junghans et al., <u>Cancer Res.</u> , 50:1495-1502 (1990)
BL	Kettleborough et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <u>Protein Eng.</u> , 4:773-783 (1991)
BM	Kirkman et al., <u>J. Exp. Med.</u> , 162:358 (1985)
BN	Kupiec-Weglinski et al., <u>Proc. Natl. Acad. Sci.</u> , 3:2624 (1986)
BO	Leonard et al., "The human receptor for T-cell growth factor," <u>J. Biol. Chem.</u> , 260:1872-1880 (1985)
BP	Liu et al., "Expression of mouse::human immunoglobulin heavy-chain cDNA in lymphoid cells," <u>Gene</u> , 54:33-40 (1987)
BQ	Maeda et al., "Construction of reshaped human antibodies with HIV-neutralizing activity," <u>Hum. Antibod. Hybrid.</u> , 2:124-134 (1991)
BR	Morrison et al., "Chimeric human antibody molecules: Mouse antigen binding-domains with human constant region domains," <u>Proc. Natl. Acad. Sci.</u> , 81:6851-6859 (1984)
BS	Morrison, S.L., "Transfectomas Provide Novel Chimeric Antibodies," <u>Science</u> , 229:1202-1207 (1985)
BT	Neuberger et al., "A hapten-specific chimeric IgE antibody with human physiological effector function," <u>Nature</u> , 314:268-270 (1985)
BU	Queen et al., "A humanized antibody that binds to the interleukin 2 receptor," <u>Proc. Natl. Acad. Sci.</u> , 86:10029-10033 (1989)
BV	Riechmann et al., "Reshaping human antibodies for therapy," <u>Nature</u> , 332:323-327 (1988)
BW	Routledge et al., "A humanized monovalent CD3 antibody which can activate homologous complement," <u>Eur. J. Immunol.</u> , 21:2717-2725 (1991)
BX	Sahagan et al., "A Genetically Engineered Murine/Human Chimeric Antibody Retains Specificity for Human Tumor-Associated Antigen," <u>J. Immunol.</u> , 137:1066-1074 (1986)
BY	Shalaby et al., "Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene," <u>J. Exp. Med.</u> , 175:217-225 (1992)
BZ	Sharon et al., "Expression of a V <sub>H</sub> C <sub>K</sub> chimaeric protein in mouse myeloma cells," <u>Nature</u> , 309:364-367 (1984)
CA	Shearman et al., "Construction, expression and characterization of humanized antibodies directed against the human $\alpha/\beta$ T cell receptor," <u>J. Immunol.</u> , 147:4366-4373 (1991)
CB	Takeda et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," <u>Nature</u> , 314:452-454 (1985)

EXAMINER

Julie (Rews, PL) DATE CONSIDERED 27 Oct 97

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT  
(Use several sheets if necessary)

Applicant: Queen

Filing Date: 6/7/95

Group: 1806

D5	Padlan, Cold Spring Harbor Symposia on Quantitative Biology, XLI(41) (1977), 627-637
D6	Saul, J. Biol. Chem., 253 (1978), 585-597
D7	Kabat, J. Immunol., 125 (1980), 961, 969
D8	Lesk and Chothia, J. Mol. Biol., 136 (1980), 225-270
D9	Stanford, J. theor. Biol., 88 (1981), 421-439
D10	Feldman, Mol. Immunol., 18 (1981), 683-698
D11	Uchiyama, J. Immunol., 126 (1981), 1393-1397
D12	Lesk and Chothia, J. Mol. Biol., 160 (1982), 325-342
D13	Davies and Metzger, Ann. Rev. Immunol., 1 (1983), 87-117
D14	Chothia and Lesk, Nature, 302 (1983), 500-505
D15	Kabat, Sequences of Proteins of Immunological Interest, US Dept. of Health and Human Services, 1983 Edition
D16	Boulianne, Nature, 312 (1984), 643-646
D17	Morrison, Proc. Natl. Acad. Sci., USA, 81 (1984) 6851-6855
D18	<del>Boss Application (Celltech Ltd.) See AM</del> See Foreign Patent Document
D19	<del>Cabilly Application (Genetech/City of Hope) See AT</del> " " " "
D20	Neuberger, Nature, 314 (1985), 651-663
D21	Chothia, J. Mol. Biol., 186 (1985), 651-663
D22	Waldmann, Science, 232 (1986), 727-732
D22	Waldmann, Cancer Res., 45 (1985) 4559-4562
D23	Amit, Science, 233 (1986), 747-753
D24	Chothia, Science, 233 (1986), 755-758
D25	Chothia and Lesk, EMBO J. 5 (1986), 823-826
D26	Jones, Nature, 321 (1986), 522-525
D27	Kabat, Sequences of Proteins of Immunological Interest, US Dept. of Health and Human Services, 1987 Edition <i>Page vii → xxvii</i>
D28	Chothia and Lesk, J. Mol. Biol., 196 (1987), 901-917
D29	Sheriff, Proc. Natl. Acad. Sci., USA 84 (1987), 8075-8079
D30	Colman, Nature, 326 (1987), 358-362
D31	Roberts, Nature, 328 (1987), 731-734
D32	<del>Winter application, See AU</del> See Foreign Patent Documents

Julie (Rews, PLS)

13 Jan 99

12-13-96

(Attachment to Paper #6)

FORM PTO-1449 (Modified)		Attorney Docket No. 11823-002630US	Serial No.: 08/484,537		
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: QUEEN et al.			
		Filing Date: June 7, 1995	Group: 1806		
Reference Designation		U. S. PATENT DOCUMENTS			
Examiner Initial	Document No.	Date	Name	Class	Sub-class
AA					
AB					
AC					
AD					
AE					
AF					
AG					
AH					
AI					
AJ					
AK					
AL					
FOREIGN PATENT DOCUMENTS					
	Document No.	Date	Country	Class	Sub-class
AM	8928874	12/21/89	Great Britain	—	—
AN	91/09967	07/11/91	World Origin	—	—
AO	0460167	12/11/91	Europe	—	—
AP					
AQ					
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
AR	Opposition by Protein Design Labs, Inc. to European Patent No. 0 460 167 of CellTech Therapeutics Limited entitled "Humanised Antibodies".				
AS					
AT					
EXAMINER	Julie (Reeves PL) DATE CONSIDERED 29 Oct 97				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		Attorney Docket No. 11823-002630US	Serial No.: 08/484,537			
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Queen et al.				
		Filing Date: 06/07/95	Group: 1806			
Reference Designation		U.S. PATENT DOCUMENTS				
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
AA						
AB						
AC						
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (yes/no)
AD	0 120 694	10/03/84	Europe	—	—	
AE	0 125 023	06/05/91	Europe	—	—	
AF	0 323 806	07/12/89	Europe	—	—	
AG	0 328 404	08/16/89	Europe	—	—	
AH	0 365 209	04/25/90	Europe	—	—	
AI	0 365 997	05/02/90	Europe	—	—	
AJ	WO 88/09344	12/01/88	WIPO	—	—	
AK						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
AL	Amit et al., Science, 233, 747-753 (1986).					
AM	Cheetham, Protein Engineering, 2(3), 170-172 (1988).					
AN	Chothia et al., J. Mol. Biol., 186, 651-663 (1985).					
AO	Chothia et al., Nature, 342, 877-883 (1989).					
AP	Chothia et al., Science, 233, 755-758 (1986).					
AQ	Chothia and Lesk, EMBO J., 5, 823-826 (1986).					
AR	Colman et al., Nature, 326, 358-362 (1987).					
AS	Davies et al., Ann. Rev. Immunol., 1, 87-117 (1983).					
AT	Davies et al., J. Biol. Chem., 263(22), 10541-10544 (1988).					
AU	Epp et al., Eur. J. Biochem., 45, 513-524 (1974).					
AV	Feldmann et al., Mol. Immunol., 18, 683-698 (1981).					
AW	Kabat, J. Immunol., 125, 961-969 (1980).					
AX	Lesk and Chothia, J. Mol. Biol., 160, 325-342 (1982).					
AY	Padlan, Mol. Immunol., 31, 169-217 (1994).					
AZ	Palm et al., Hoppe Seyler's Z. Physiol. Chem., 354(12), 1651-1654 (1973). Abstract.					
BA	Palm et al., Hoppe Seyler's Z. Physiol. Chem., 356, 167-191 (1975). Abstract only.					
BB	Panka et al., PNAS-USA, 85, 3080-3084 (1988).					
BC	Roberts et al., Nature, 328, 731-734 (1987)					

Julie Reeves, P.D.

27 Oct 97

FORM PTO-1449 (Modified)

Attorney Docket No.  
11823-002630USSerial No.:  
08/484,537LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT  
(Use several sheets if necessary)

Applicant: Queen et al.

Filing Date: 06/07/95 Group: 1806

BD	Saul et al., J. Biol. Chem., <u>253</u> (2), 585-597 (1978).
BE	Sheriff et al., PNAS-USA, <u>84</u> , 8075-8079 (1987).
BF	Stanford and Wu, J. Theor. Biol., <u>88</u> , 421-439 (1981).
BG	Tramontano et al., J. Mol. Biol., <u>215</u> , 175-182 (1990).
BH	Verhoeven et al., BioEssays, <u>8</u> (2), 74-78 (1988).
BI	Waldmann et al., Cancer Research, <u>45</u> , 4559s-4562s (1985).
BJ	Wu and Kabat, J. Exp. Med., <u>132</u> , 211-250 (1970).
BK	

EXAMINER

Julie Rees, PhD

DATE CONSIDERED

27 Oct 97

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.